Concord Biotech

June 25 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH - COMPLETES PPB (KENYA) AND NDA (UGANDA) INSPECTION AT UNIT-II FORMULATION FACILITY

Source text: ID:nBSE7xbDYz

Further company coverage: CONB.NS

(([email protected];))

June 12 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH - COMPLETES ANVISA INSPECTION AT LIMBASI API MANUFACTURING FACILITY

Source text: ID:nBSE6p6bxg

Further company coverage: CONB.NS

(([email protected];;))

Concord Biotech has received approval from the U.S. Food and Drug Administration for its generic version of Tofacitinib tablets in 5 mg and 10 mg strengths, a treatment used for several autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The U.S. market for the drug is estimated at approximately $500 million annually, positioning the Ahmedabad-based pharmaceutical firm to tap into a substantial revenue opportunity. The approval aligns with the company's strategy to expand its presence in the American generics market, which has been a key growth priority amid recent revenue headwinds.

Powered by Tijori

June 10 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH - GETS ABBREVIATED NEW DRUG APPLICATION APPROVAL FOR TOFACITINIB TABLETS, 5 MG AND 10 MG

• CONCORD BIOTECH - RECEIVED APPROVAL FROM U.S. FOOD AND DRUG ADMINISTRATION FOR TOFACITINIB TABLETS

Source text: ID:nBSE9fqdg4

Further company coverage: CONB.NS

(([email protected];;))

June 2 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD- RECEIVED APPROVAL FROM USFDA FOR ITS ANDA FOR MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION USP, 200 MG/ML

Source text: ID:nBSE79MRKK

Further company coverage: CONB.NS

(([email protected];))

** Shares of India's Concord Biotech CONB.NS down 1.48% at 1,066.40 rupees

** Brokerage Citi cuts TP of CONB to 1,190 rupees from 1,680 rupees, citing slower revenue growth in its core drug ingredient sales business and formulations business

** Maintains "neutral" rating and says slower growth expected to compress margins

** Brokerage lowers FY26–FY27 EPS estimates by 20%–23%, cuts FY27–FY28 revenue growth forecast to about 14% from 17%–18% earlier

** Says growth hit by tariff-related uncertainties, tender deferrals in the Middle East and delays from India's drug regulator CDSCO

** YTD, stock down ~20%

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

Feb 11 (Reuters) - Concord Biotech Ltd CONB.NS:

• DEC-QUARTER CONSOL NET PROFIT 644.8 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 2.78 BILLION RUPEES

Source text: ID:nBSEcbrLxC

Further company coverage: CONB.NS

(([email protected];))

Dec 8 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH - CFO LALIT SETHI TO RETIRE EARLY EFFECTIVE JANUARY 5, 2026

Source text: ID:nBSE79y10m

Further company coverage: CONB.NS

(([email protected];))

Nov 13 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD - APPROVES ACQUISITION OF 100% EQUITY IN CELLIIMUNE BIOTECH

• CONCORD BIOTECH LTD - APPROVES 100 MILLION RUPEES INVESTMENT IN SOLAR POWER PROJECT

Source text: ID:nBSERlqFm

Further company coverage: CONB.NS

(([email protected];))

July 2 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD - TO EXPAND OPERATIONS IN USA

Source text: ID:nBSE6lXpch

Further company coverage: CONB.NS

(([email protected];))

** Concord Biotech CONB.NS shares jump nearly 4% to 1,732 rupees

** Drugmaker extends gains to fourth straight session

** Q4 consol net profit jumps 48% as 35% rev surge outpaces rise in costs

** Trading volume 525k shares vs about 194k 30-day avg

** YTD stock has fallen 21%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

April 8 (Reuters) - Concord Biotech Ltd CONB.NS:

• GRANTED APPROVAL FROM USFDA FOR MARKETING ITS TERIFLUNOMIDE TABLETS

Source text: [ID:]

Further company coverage: CONB.NS

(([email protected];;))

March 25 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD - COMMENCES PRODUCTION AT NEW VALTHERA FACILITY

• CONCORD BIOTECH - COMMENCED PRODUCTION OF INJECTABLE AT CO'S FACILITY SITUATED AT VALTHERA

Further company coverage: CONB.NS

(([email protected];))

March 4 (Reuters) - Concord Biotech Ltd CONB.NS:

• APPROVES 61 MILLION RUPEES INVESTMENT IN CLEAN MAX

Source text: ID:nBSE2cDJRT

Further company coverage: CONB.NS

(([email protected];;))

Feb 20 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH - MFDS COMPLETES INSPECTION AT CONCORD BIOTECH'S DHOLKA UNIT

Source text: ID:nBSE22Hs9D

Further company coverage: CONB.NS

(([email protected];))

Jan 16 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD - ENTERS SHARE PURCHASE AGREEMENT WITH CLEAN MAX

• CONCORD BIOTECH LTD - TO ACQUIRE 26% EQUITY SHARES OF CLEAN MAX

Source text: ID:nBSE9PW3L5

Further company coverage: CONB.NS

(([email protected];;))

Dec 12 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD - INVESTS $1 MILLION IN PALVELLA THERAPEUTICS

Source text: ID:nBSE7rWrnV

Further company coverage: CONB.NS

(([email protected];))

Nov 11 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH SEPT-QUARTER CONSOL NET PROFIT 957.4 MILLION RUPEES

• CONCORD BIOTECH SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.1 BILLION RUPEES

Source text: ID:nBSECTmNG

Further company coverage: CONB.NS

(([email protected];))

** Shares of Concord Biotech CONB.NS surge as much as 12.6% to a record high of 1,815 rupees; last up 5.4%

** Reuters could not immediately ascertain a reason for the stock's move

** Biopharma firm eyes busiest session since late-May, volumes at 28.3x the 30-day avg

** Including session's gains, stock up ~16% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

June 5 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH - HEALTH PRODUCT REGULATORY AUTHORITY OF IRELAND HAS ISSUED EUGMP CERTIFICATE FOR CO'S UNIT II AT DHOLKA, AHMEDABAD

Source text for Eikon: ID:nBSE3Y0cvZ

Further company coverage: CONB.NS

(([email protected];))

** Shares of Concord Biotech CONB.NS up 2.8% in above-average vol

** Biopharma says Kenya's Ministry of Health Pharmacy gave its Ahmedabad facility good manufacturing practices certificate

** Session's gains help CONB turn positive for the week

** Stock up ~1.5% so far this week

** CONB sees its second most active session of the year, more than 450,000 shares traded as of 12:30 p.m. IST

** The stock is up ~60% since listing in Aug 2023

(Reporting by Nishit Navin in Begaluru)

(([email protected];))

Feb 22 (Reuters) - Concord Biotech Ltd CONB.NS:

• CONCORD BIOTECH LTD - MINISTRY OF HEALTH PHARMACY AND POISONS BOARD, REPUBLIC OF KENYA HAD CONDUCTED INSPECTION OF UNIT II

• CONCORD BIOTECH LTD - CLOSURE OF INSPECTION OF KENYA'S MINISTRY OF HEALTH PHARMACY AND POISONS BOARD, AT VALTHERA UNIT

• CONCORD BIOTECH LTD - COMPLETED WITHOUT ANY ADVERSE REMARKS, CO RECEIVED CERTIFICATE OF GOOD MANUFACTURING PRACTICES

Source text for Eikon: ID:nNSE8SyWkj

Further company coverage: CONB.NS

(([email protected];))

Feb 8 (Reuters) - Concord Biotech Ltd CONB.NS:

• DEC-QUARTER CONSOL NET PROFIT 775.7 MILLION RUPEES VERSUS PROFIT 773.7 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 2.41 BILLION RUPEES VERSUS 2.41 BILLION RUPEES

Source text for Eikon: ID:nNSE9ppgYT

Further company coverage: CONB.NS

(([email protected];))

By Rama Venkat

BENGALURU, Nov 1 (Reuters) - Indian kitchenware products maker Cello World's initial public offering (IPO) was oversubscribed by nearly 40 times, higher than similar IPOs recently, inviting bids worth 556.19 billion rupees ($6.7 billion), exchange data showed on Wednesday.

Investors bid for more than 858.3 million shares, compared with the 22 million shares on offer, with institutional investors showing the most interest, the data showed.

"Despite markets being on weaker note, Cello World offer received an overwhelming response, although retail investors remained cautious as IPO has only an offer for share sale from existing stakeholders," said Prashant Tapse, senior vice president (research) at Mehta Equities.

Cello World's shareholders -- including its promoters, an Indian market term for large shareholders who can influence company policy -- are selling stock worth 19 billion rupees in the IPO, while the company itself if not offering any shares.

Other IPOs where the company did not sell shares have seen tepid interest. For example, the IPOs of Blue Jet Healthcare BLUJ.NS, Mankind Pharma MNKI.NS and Concord Biotech CONB.NS were oversubscribed 7-27 times.

Cello World has set a price band of 617-648 rupees per share for the IPO. At the top end, it will be valued at 137.53 billion rupees, three times rival Borosil's BORS.BO market value and nearly seven times that of Stovekraft STVE.NS and Butterfly Gandhimathi Appliances BUTT.NS.

"On valuation, it seems the issue is reasonably priced, reflecting an expected revenue and profit growth," said Tapse.

The company's consolidated net profit jumped 25.2% year-over-year to 774.4 million rupees in the quarter ended June 30, while revenue rose 9%.

In that same period, Borosil's profit shrunk 62.5% due to higher raw material costs, while revenue climbed 16%.

Cello World is expected to list on the stock exchanges on Monday.

Kotak Mahindra Capital and ICICI Securities were among the lead IPO's managers.

($1 = 83.2840 Indian rupees)

(Reporting by Rama Venkat in Bengaluru; Editing by Savio D'Souza)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))

Adds details on IPO in paragraphs 4 and 6, analyst comment in paragraph 5

By Rama Venkat

BENGALURU, Oct 26 (Reuters) - Shares of IRM Energy IRME.NS fell as much as 10.9% in trading debut on Thursday, valuing the Indian natural gas distributor at 18.48 billion rupees ($222.03 million) in a weak market.

The stock fell to a low of 450 rupees in early trade after opening at 477.25 rupees. Its initial public offer (IPO) price was at 505 rupees.

The benchmark Nifty 50 .NSEI was down 1.3%, while the more domestically-focused mid-cap .NIFMDCP100 and small-cap .NIFSMCP100 stocks declined more than 2% each. .BO

Investors bid for about 206.3 million IRM Energy shares by the final day of subscription, 27.05 times more than the 7.6 million shares on offer, exchange data showed.

"The IPO was well-received by investors and oversubscribed. However, the current market condition could be a reason behind a poor listing," said Shivani Nyati, head of wealth at Swastika Investmart.

The company, with a diversified customer portfolio and distribution network, is well-positioned to benefit from the growing demand for natural gas in India, Nyati added.

The IPO of IRM Energy, a group company of Cadila Pharmaceuticals, comprised of fresh issue of 10.8 million shares worth 5.44 billion rupees, according to the prospectus.

The company plans to use about 3 billion rupees of proceeds from the IPO to fund the development of the gas distribution network in Namakkal and Tiruchirappalli in the southern state of Tamil Nadu.

The Ahmedabad-based company builds, operates and expands the gas distribution network for industrial, domestic and automobile customers.

HDFC Bank and BOB Capital Markets were book-running lead managers for the IPO.

So far this year, 173 Indian companies have gone public, raising $4.46 billion, compared with 115 companies that raised $6.06 billion in the same period last year, according to LSEG data.

($1 = 83.2325 Indian rupees)

(Reporting by Rama Venkat in Bengaluru;Editing by Nivedita Bhattacharjee and Eileen Soreng)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))

** Shares of India's Concord Biotech CONB.NS jump as much as 8% at 1,177 rupees, hitting a record high since its listing on Aug. 18

** Stock on track for a second consecutive session gains if trends hold

** Global brokerage Jefferies initiates coverage with "buy" and TP at 1,260 rupees, implying 19% upside

** Co targets fermentation-based products, which have high entry barriers; its efficient manufacturing process has given it market leadership in select immunosuppressant and antibacterial APIs - Jefferies

** Adds, a wide portfolio and adequate capacities should drive revenue growth and operating leverage; estimates 30% PAT CAGR (compound annual growth rate) over FY 23-26

** More than 370,000 shares change hands by 1:28 p.m. IST, vs 30-day avg of 292,324

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

BENGALURU, Oct 3 (Reuters) - Shares of JSW Infrastructure JSWN.NS, India's No.2 commercial port operator, jumped 20.17% in pre-open trade on Tuesday, valuing the company at 300.30 billion rupees ($3.61 billion) and setting it on course to join a host of other successful domestic debutantes.

The stock was at 143 rupees in pre-open trade, compared with its initial public offer (IPO) price of 119 rupees.

JSW Infra is part of the billionaire Sajjan Jindal-led JSW Group and is the first business of the steel-to-software conglomerate to go public since JSW Energy JSWE.NS in 2010.

The company raised 28 billion rupees by selling fresh shares. JSW Group did not sell any shares.

The company is set to follow a host of successful debutantes in the past few months -- ranging from cable maker RR Kabel RRKA.NS to Concord Biotech CONB.NS -- helped by robust investor appetite that has also powered the blue-chip stock market index to a record high.

So far this year, 227 Indian companies have gone public, raising $6.62 billion, compared with 172 companies that raised $10.53 billion in the same period last year, according to LSEG data.

JSW Infra's profit more than doubled to 7.50 billion rupees in fiscal 2023, while its revenue jumped about 41% to 31.95 billion rupees, according to its IPO prospectus.

The company plans to use the IPO proceeds to fund expansion projects and repay debt, which was 22.16 billion rupees as of March 31.

JSW Infra aims to nearly double its operational capacity to 300 million tonnes per annum (MTPA) by 2030, but that would still trail Adani Ports's APSE.NS current capacity of about 558 MMTPA.

Adani Ports, a listed unit of billionaire Gautam Adani's namesake conglomerate, has a market value of about 1.78 trillion rupees.

Axis Capital, Credit Suisse Securities (India) and Kotak Mahindra Capital were among the lead managers for the IPO.

($1 = 83.1840 Indian rupees)

(Reporting by Rama Venkat in Bengaluru; Editing by Savio D'Souza)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))

BENGALURU, Sept 27 (Reuters) - Indian commercial port operator JSW Infrastructure received bids worth 606.13 billion rupees ($7.29 billion) in its initial public offering (IPO), exchange data showed on Wednesday.

The JSW Group-owned company received bids for 5.09 billion shares at between 113 and 119 rupees, 37.37 times more than the 136.3 million shares offered, National Stock Exchange data showed, with institutional investors showing the most interest.

The IPO of India's second-largest commercial port operator in terms of cargo handling capacity was JSW Group's first since JSW Energy in 2010, and comprised of fresh issue of shares worth up to 28 billion rupees.

JSW Energy JSWE.NS debuted in January 2010, and has since risen more than four-fold in value.

JSW Infra, which competes with Adani Ports APSE.NS and Gujarat Pipavav Port GPPL.NS, is due to be listed on Indian exchanges next week.

The company plans to use proceeds from the IPO to repay certain borrowings and invest in expansion projects at its units JSW Jaigarh Port and JSW Mangalore Container Terminal. It had a net debt of 22.16 billion rupees as of March 31, 2023.

It also plans to expand its operational capacity to up to 300 million tonnes per annum (MTPA) across its ports and terminals by 2030 from around 158 MTPA currently.

In comparison, Adani Ports had a total operating capacity of 558 MMTPA as on March 31.

JSW Infra's profit for fiscal 2023 more than doubled to 7.50 billion rupees year-on-year, while its revenue from operations rose 40.6% to 31.95 billion rupees, its IPO prospectus showed.

The listing would follow successful debuts by companies like Aeroflex Industries AERO.NS and Concord Biotech CONB.NS in the past few days owing to improved domestic appetite, and robust foreign and domestic fund inflows.

($1 = 83.1854 Indian rupees)

(Reporting by Rama Venkat in Bengaluru; Editing by Varun H K)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))

Sept 6 (Reuters) - Concord Biotech Ltd CONB.NS:

• JUNE-QUARTER CONSOL NET PROFIT 544.9 MILLION RUPEES VERSUS PROFIT 492.6 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.95 BILLION RUPEES VERSUS 1.81 BILLION RUPEES

Source text for Eikon: ID:nBSE1tdgzl

Further company coverage: CONB.NS

(([email protected];))

BENGALURU, Aug 18 (Reuters) - Shares of Indian biopharma company Concord Biotech CONB.NS pre-opened 21.5% higher at 900.05 rupees ($10.83) in debut trading on Friday, compared with the initial public offer (IPO) price of 741 rupees.

($1 = 83.1025 Indian rupees)

(Reporting by Rama Venkat in Bengaluru; Editing by Janane Venkatraman)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))